'Beyond our expectations': How to invest in obesity drugs like Ozempic with ASX ETFs

This could be your way to invest in obesity drugs.

medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The ResMed Inc (ASX: RMD) share price has come under significant pressure in recent months due to the emergence of obesity drugs.

With analysts forecasting huge growth in demand for drugs like Ozempic over the next decade, there are concerns that ResMed could lose some of its sleep apnoea customer base. That's because research shows that 70% of obstructive sleep apnoea (OSA) patients are obese.

The good news is that most analysts believe this is an overreaction and that there's still a huge market for ResMed to grow into outside any Ozempic impacts.

But what about Ozempic and other obesity drugs? Should we be investing in them as well?

The team at Morgan Stanley believes it could be a good idea based on its expectations for explosive growth through to 2030.

Morgan Stanley's European Biopharmaceuticals analyst, Mark Purcell, commented:

Social media activity documenting transformative weight loss, together with the establishment of affordable insurance coverage more quickly than anticipated, has helped drive demand for obesity medicines beyond our expectations. While supply constraints have capped sales growth in the near term, the global obesity market could go from a $2.4 billion category in 2022 to reach $77 billion in 2030, up from our previous estimate for a $54 billion.

ASX ETFs to the rescue

The simplest way to invest in Ozempic and other obesity drugs is to go directly to the source.

In the case of Ozempic, this would mean investing in Danish pharmaceutical giant Novo Nordisk (NYSE: NVO), which is listed on Wall Street.

As for Mounjaro, a diabetes treatment being repurposed as an obesity drug, it is owned by US pharmaceutical behemoth Eli Lilly And Co (NYSE: LLY).

However, if you're not keen on going down this route, then you could look at ASX ETFs.

The VanEck Global Healthcare Leaders ETF (ASX: HLTH) gives investors access to 50 of the largest international companies from the global healthcare sector. Its holdings include both Eli Lilly & Co and Novo Nordisk.

Alternatively, the BetaShares Global Healthcare ETF – Currency Hedged (ASX: DRUG) could be another way to do it. It is invested in a touch under 70 global healthcare shares, with Eli Lilly & Co and Novo Nordisk making up a total weighting of 12.9% of the portfolio.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Novo Nordisk. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ETFs

A man sees some good news on his phone and gives a little cheer.
ETFs

3 exciting ASX ETFs to buy and hold for 10 years

Let's see what these exciting funds provide investors with access to.

Read more »

Woman looks amazed and shocked as she looks at her laptop.
ETFs

$10,000 invested in ARMR ETF a year ago is now worth…

This ASX ETF is a relatively new listing and it's shooting the lights out.

Read more »

Woman and man calculating a dividend yield.
ETFs

What is the dividend yield of the Vanguard MSCI Index International Shares ETF (VGS)?

Is this major fund an attractive option for passive income?

Read more »

Australian dollar notes in the pocket of a man's jeans, symbolising dividends.
ETFs

The best ASX ETFs to buy with $1,000

Investors with money to put into the market might want to check out these funds.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
ETFs

5 ASX ETFs to ride the next bull market

Check out these funds that could thrive during the next bull market.

Read more »

Seven men and women of different ages and nationalities put their heads together and smile as they look down at the camera.
ETFs

Here's how I would build a $100,000 ETF portfolio for ultimate ASX diversification today

You can get an incredible level of diversification using ETFs.

Read more »

Suncorp share price Businessman cheering and smiling on smartphone
ETFs

4 ASX ETFs for smart investors to buy

Let's see what these funds offer investors right now.

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
ETFs

5 ASX ETFs to buy with $5,000 in June

Let's see what sort of stocks these funds are invested in.

Read more »